Neal Bhutiani

Assistant Professor

University of Louisville
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Year:

2026

Year:

2026

Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors. Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer (n = 718). We then identified patients with appendiceal adenocarcinoma at our institution (from October 2004–September 2022) for whom ctDNA mutation profiling (liquid biopsy) was performed (n = 168) and extracted clinicopathologic and outcomes data. Of these 168 patients, 57 also had tissue-based tumor mutational profiling, allowing for evaluation of concordance between liquid and tissue assays. Results: The mutational landscape of ctDNA in appendiceal adenocarcinoma is distinct from tissue-based sequencing, with TP53 being the most frequently mutated (46%). Relative to other tumors, appendiceal adenocarcinoma seems less likely to shed ctDNA, with only 38% of patients with metastatic appendiceal adenocarcinoma having detectable ctDNA (OR = 0.26; P < 0.0001 relative to colorectal cancer). When detectable, the median variant allele frequency was significantly lower in appendiceal adenocarcinoma (0.4% vs. 1.3% for colorectal cancer; P ≤ 0.001). High-grade, signet ring, or colonic-type histology, metastatic spread beyond the peritoneum, and TP53 mutation were associated with detectable ctDNA. With respect to clinical translation, patients with detectable ctDNA had worse overall survival (HR = 2.32; P = 0.048). In the Guardant Health cohort, actionable mutations were found in 93 patients (13.0%). Conclusions: Although metastatic appendiceal adenocarcinoma tumors are less likely to shed tumor DNA into the blood relative to colorectal cancer, ctDNA profiling in appendiceal adenocarcinoma has clinical utility.

Year:

2025

Year:

2025

Background The objective of this study is to assess the possible association between intraoperative anesthesia team handovers and increased 90‐day major complications following HPB surgery. Methods This is a single‐center retrospective cohort study of patients who underwent HPB surgery. Anesthesiologist handover (AH) occurred when a complete transfer of care to a receiving anesthesiologist. total anesthesia team handovers (TH) occurred when both anesthesiologist and supervised provider transferred care. The primary outcome was 90‐day major complications, defined as an ACCORDION score of ≥ 3. Results Ninety‐day major complications occurred in 35 (21.6%) of TH and 96 (21.9%) of AH patients. With adjustment of other covariates, no significant association was found between AH (OR, 1.358, 95% CI, 0.935–1.973, p = 0.1079) or TH (OR, 1.157, 95% CI, 0.706–1.894, p = 0.5633) and 90‐day major complications. Conclusions In a high‐volume HPB center, anesthesia team handovers were not associated with an increased risk of patients having a major complication within 90 days after HPB surgery.

Year:

2025

The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC‐PM). An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique. Two rounds of voting were performed to assess agreement levels on two clinical management pathways regarding synchronous and metachronous CRC‐PM. Supporting evidence was evaluated via rapid literature reviews. The overall level of evidence was low in the existing literature. Of 145 participants in the first round, 136 (96.8%) responded in the second round. Over 90% consensus was achieved in most pathway blocks. For both pathways, early referral to a peritoneal surface malignancy center should be made for patients with CRC‐PM. For the synchronous pathway, upfront cytoreductive surgery was deemphasized in favor of systemic therapy. For the metachronous pathway, risk stratification via clinical and pathological features was revised. For both pathways, surveillance strategies were added, including only a weak recommendation for circulating tumor DNA testing, given limited evidence of its utility in detecting and monitoring PM. The consensus‐driven clinical pathways provide valuable guidance for the management of CRC‐PM. There remains a need for high‐quality evidence and prospective multicenter trials in this domain.

Year:

2025

Year:

2025

Year:

2025

Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors. Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer ( n = 718). We then identified patients with appendiceal adenocarcinoma at our institution (from October 2004–September 2022) for whom ctDNA mutation profiling (liquid biopsy) was performed ( n = 168) and extracted clinicopathologic and outcomes data. Of these 168 patients, 57 also had tissue-based tumor mutational profiling, allowing for evaluation of concordance between liquid and tissue assays. Results: The mutational landscape of ctDNA in appendiceal adenocarcinoma is distinct from tissue-based sequencing, with TP53 being the most frequently mutated (46%). Relative to other tumors, appendiceal adenocarcinoma seems less likely to shed ctDNA, with only 38% of patients with metastatic appendiceal adenocarcinoma having detectable ctDNA (OR = 0.26; P P ≤ 0.001). High-grade, signet ring, or colonic-type histology, metastatic spread beyond the peritoneum, and TP53 mutation were associated with detectable ctDNA. With respect to clinical translation, patients with detectable ctDNA had worse overall survival (HR = 2.32; P = 0.048). In the Guardant Health cohort, actionable mutations were found in 93 patients (13.0%). Conclusions: Although metastatic appendiceal adenocarcinoma tumors are less likely to shed tumor DNA into the blood relative to colorectal cancer, ctDNA profiling in appendiceal adenocarcinoma has clinical utility.

Year:

2025

Multidisciplinary management of rectal cancer has rapidly evolved over the last several years. This review describes recent data surrounding total neoadjuvant therapy, organ preservation, and management of lateral pelvic lymph nodes. It then presents our treatment algorithm for management of rectal cancer at The University of Texas MD Anderson Cancer Center in the context of this and other existing literature. As part of this discussion, the review describes how we tailor management based upon both patient and tumor‐related factors in an effort to optimize patient outcomes.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (18)

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kanwal Raghav

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Thomas

Assistant Professor, Surgical Oncology / HPB Surgery

Medical University of South Carolina

UNITED STATES
View details

John Paul Shen

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Abhineet Uppal

Assistant Professor

Emory University

UNITED STATES
View details

Ching‐Wei D. Tzeng

-

UNITED STATES
View details

Jason Willis

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Melissa Taggart

Associate professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Carlos HF Chan

Emory University

UNITED STATES
View details

Mohammad Haroon Asif Choudry

Professor of Surgery. Director, David C. Koch Regional Perfusion Cancer Therapy Center

University of Pittsburgh Medical Center

UNITED STATES
View details

Beth Helmink

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael White

Assistant Professor

-

UNITED STATES
View details

Michael J. Overman

-

UNITED STATES
View details

Jenny Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy Newhook

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kurt Schultz

Yale University

UNITED STATES
View details

keith fournier

Associate Professor of Surgery

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Quan Ly

Professor

University of Nebraska Medical Center

UNITED STATES
View details